Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jingjun Qiu

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Oncology Letters|July 17, 2018
Association of the characteristics of B- and T-cell repertoires with papillary thyroid carcinomaGuoping Sun, Lumei Qiu, Zhiqiang Cheng, et al.
Patient Preference and Adherence|December 28, 2018
Patient-reported outcomes in individuals with hepatitis C virus infection treated with elbasvir/grazoprevirXinyi Ng, Chizoba Nwankwo, Jean Marie Arduino, et al.
Human Vaccines & Immunotherapeutics|April 1, 2017
Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: A randomized controlled non-inferiority clinical trialJingjun Qiu, Yunkai Yang, Lirong Huang, et al.
Hepatology (Baltimore, Md.)|March 4, 2017
Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III StudyChristophe Hézode, Massimo Colombo, Marc Bourlière, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2020
A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive <i>TP53</i>-mutant Ovarian CancerAmit M Oza, Maria Estevez-Diz, Eva-Maria Grischke, et al.
Journal of Hepatology|August 21, 2016
Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trialJan Sperl, Gabor Horvath, Waldemar Halota, et al.
Advances in Therapy|June 30, 2022
Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 TrialJingxin Li, Ai-Min Hui, Xiang Zhang, et al.
The Lancet Regional Health. Western Pacific|September 19, 2022
Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trialAi-Min Hui, Jingxin Li, Li Zhu, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Oncology Letters|July 17, 2018
Association of the characteristics of B- and T-cell repertoires with papillary thyroid carcinomaGuoping Sun, Lumei Qiu, Zhiqiang Cheng, et al.
Patient Preference and Adherence|December 28, 2018
Patient-reported outcomes in individuals with hepatitis C virus infection treated with elbasvir/grazoprevirXinyi Ng, Chizoba Nwankwo, Jean Marie Arduino, et al.
Human Vaccines & Immunotherapeutics|April 1, 2017
Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: A randomized controlled non-inferiority clinical trialJingjun Qiu, Yunkai Yang, Lirong Huang, et al.
Hepatology (Baltimore, Md.)|March 4, 2017
Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III StudyChristophe Hézode, Massimo Colombo, Marc Bourlière, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2020
A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive <i>TP53</i>-mutant Ovarian CancerAmit M Oza, Maria Estevez-Diz, Eva-Maria Grischke, et al.
Journal of Hepatology|August 21, 2016
Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trialJan Sperl, Gabor Horvath, Waldemar Halota, et al.
Advances in Therapy|June 30, 2022
Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 TrialJingxin Li, Ai-Min Hui, Xiang Zhang, et al.
The Lancet Regional Health. Western Pacific|September 19, 2022
Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trialAi-Min Hui, Jingxin Li, Li Zhu, et al.
Pageof 2